



PATIENT INFORMATION (Complete or Fax Existing Chart)	PRESCRIBER INFORMATION
Name: _____ DOB: _____ Address: _____ City, State, Zip: _____ Phone: _____ Alt. Phone: _____ Email: _____ SS#: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F Weight: _____ (lbs) Ht: _____ Allergies: _____	Prescriber Name: _____ State License: _____ NPI #: _____ Tax ID: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ Office Contact: _____ Phone: _____

INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)	
Primary Insurance: _____ Plan #: _____ Group #: _____ RX Card (PBM): _____ BIN: _____ PCN: _____	Secondary Insurance (If Applicable): _____ Plan #: _____ Group #: _____ RX Card (PBM): _____ BIN: _____ PCN: _____

CLINICAL INFORMATION			
<input type="checkbox"/> G35.A Relapsing-remitting multiple sclerosis	<input type="checkbox"/> G35.B0 Primary progressive multiple sclerosis, unspecified	<input type="checkbox"/> G35.B1 Active primary progressive multiple sclerosis	<input type="checkbox"/> G35.B2 Non-active primary progressive multiple sclerosis
<input type="checkbox"/> G35.C0 Secondary progressive multiple sclerosis, unspecified	<input type="checkbox"/> G35.C1 Active secondary progressive multiple sclerosis	<input type="checkbox"/> G35.CD Non-active secondary progressive multiple sclerosis	<input type="checkbox"/> G35.D Multiple sclerosis, unspecified
<input type="checkbox"/> Other (Specify ICD-10 Code): _____			
Has the patient been tested for JCV virus? <input type="checkbox"/> Yes <input type="checkbox"/> No JCV Index: _____			
Line Access: <input type="checkbox"/> PIV <input type="checkbox"/> Port <input type="checkbox"/> PICC <input type="checkbox"/> Midline Is Patient enrolled in TYSABRI® TOUCH® Program? <input type="checkbox"/> Yes <input type="checkbox"/> No			

DRUG ORDERS			
Prescription type: <input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Continued therapy		Total Doses Received: _____	Date of Last Injection/Infusion: _____
Medication	Dose/Strength	Directions	Refills
<input type="checkbox"/> Tysabri® (Natalizumab)	<input type="checkbox"/> 300mg/15ml Vial <input type="checkbox"/> Other: _____	<input type="checkbox"/> Infuse 300mg IV over 1 hour every 4 weeks <input type="checkbox"/> Other: _____	_____
Pre-Medication	Dose/Strength	Directions	
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> 500mg	<input type="checkbox"/> Take 1-2 tablets PO prior to infusion or post-infusion as directed	
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> 25mg IV/PO <input type="checkbox"/> 50mg IV/PO	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed OR <input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed	
<input type="checkbox"/> Methylprednisolone	<input type="checkbox"/> 40mg <input type="checkbox"/> 100mg <input type="checkbox"/> 125mg	<input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed <input type="checkbox"/> Other: Inject 100mg IV 30 minutes prior to infusion	
<input type="checkbox"/> _____	_____	_____	

INFUSION REACTION ORDERS
<b>Mild reaction protocol:</b> <input checked="" type="checkbox"/> Diphenhydramine 25mg IV, one time, for pruritus. <i>If symptoms worsen, see orders for moderate to severe reactions.</i>

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



<p><b>Moderate reaction protocol:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Acetaminophen 650mg PO, one time, for pyrexia or rigors</li> <li><input checked="" type="checkbox"/> Diphenhydramine 50mg IV, one time, for pruritus or urticaria</li> <li><input checked="" type="checkbox"/> Famotidine 20mg IV, one time, for, for pruritus or urticaria</li> <li><input checked="" type="checkbox"/> Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms</li> </ul> <p><i>If symptoms worsen, see interventions for severe reactions</i></p> <p><b>Severe reaction protocol: (Call 911 if initiated):</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (&gt;95%)</li> <li><input checked="" type="checkbox"/> Diphenhydramine 50mg IV,one time, for respiratory symptoms, edema, or anaphylaxis</li> <li><input checked="" type="checkbox"/> Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis</li> <li><input checked="" type="checkbox"/> Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms</li> <li><input checked="" type="checkbox"/> Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen</li> </ul>		
<b>FLUSHING &amp; LOCKING ORDERS</b>		
Flushing Protocol (>66lbs/33kg)		
<p><b>PIV and Midline:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion</li> </ul>	<p><b>Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw</li> </ul>	
Locking Protocol (>66lbs/33kg)		
<p><b>PIV and Midline:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush</li> </ul>	<p><b>PICC:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush</li> </ul>	<p><b>Implanted Port, Tunneled Catheter, and Non-tunneled Catheter:</b></p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush</li> </ul>
<p><b>** May substitute Dextrose 5% in Water, or alternative, for 0.9% Sodium Chloride, when indicated due to incompatibility with medications being infused</b></p>		
<b>SIGNATURE</b>		
<p>We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.</p>		
<p>X _____ Prescriber Signature</p>		<p>Date: _____</p>

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.